IP Library › Granted Patent US 12,331,318
Granted Patent B2
US 12,331,318 · App. 17/259,900 · Granted Jun 17, 2025

Non-immunogenic engineered tissue and methods of producing and using the same

Inventor: Lothar Germeroth (Goettingen, DE)
C12N5/0657C12N2500/90C12N2510/00
View Patent ↗
Loading inventors, assignments & file history…
Monitor This Case
Get email alerts when status or documents change.
Order Certified Copies
Most orders are placed with the USPTO same day — all within 24 business hours.
Order via The Patent Place →
Pre-filled with this patent's details
Quick Facts
Patent No.
US 12,331,318
App. No.
17/259,900
Granted
Jun 17, 2025
Kind
B2
Abstract

The invention provides a method of producing a non-immunogenic (bio)engineered tissue from pluripotent stem cells or pluripotent stem cell derivatives, the respective cells being deficient of MHC class I molecules and comprising an immunomodulatory protein on their surface, wherein the method comprises inducing the differentiation of the pluripotent stem cells into a cell type that is essential for the function of the engineered tissue under conditions that also allow the formation of the engineered tissue, thereby rendering the engineered tissue to be non-immunogenic to a recipient of the engineered tissue. The present invention further relates to an engineered tissue, a pharmaceutical composition comprising the engineered tissue, medical treatments using the engineered tissue and uses of the engineered tissue.

Claims (25)

1. A method of producing a non-immunogenic engineered heart muscle tissue from pluripotent stem cells, comprising:

modifying ND50039 pluripotent stem cells to provide modified ND50039 pluripotent stem cells comprising (i) a deletion of the β2-Microglobulin (B2M) gene endogenous to wild-type ND50039 cells, thereby preventing cell-surface expression of endogenous HLA-A, B, and C by the modified ND50039 cells, and (ii) introduction of an expression construct configured to drive cell-surface expression of an exogenous immunomodulatory fusion protein comprising at least a portion of B2M covalently linked to at least a portion of an HLA class Iα chain by the modified ND50039 cells;

differentiating the modified ND50039 pluripotent stem cells into at least one first cell type that is essential for the function of the engineered heart muscle tissue, wherein the first cell type is a cardiomyocyte;

differentiating the modified ND50039 pluripotent stem cells into at least one second cell type that forms a supporting component for the first cell type within the engineered heart muscle tissue as a separate cell population from the first cell type, wherein the second cell type is a fibroblast; and

mixing the first cell type and the second cell type at a defined ratio in the presence of a biocompatible extracellular matrix to form the engineered heart muscle tissue,

wherein the engineered heart muscle tissue is non-immunogenic to a recipient of the engineered heart muscle tissue.

2. The method of claim 1 , wherein the engineered heart muscle tissue

(a) is not recognized as allogenic by effector T cells, and/or

(b) is resistant to NK-mediated lysis.

3. The method of claim 1 , wherein the HLA class Iα chain is selected from the group consisting of HLA-A, HLA-B, HLA-C, HLA-E, HLA-F and HLA-G.

4. The method of claim 1 , wherein the exogenous immunomodulatory fusion protein comprises at least a portion of B2M and at least a portion of HLA-A.

5. The method of claim 4 , wherein the HLA-A is HLA-A0201.

6. The method of claim 1 , wherein the modified ND50039 pluripotent stem cells further express a target peptide antigen that is presented by the immunomodulatory fusion protein on the cell surface.

7. The method of claim 6 , wherein the target peptide antigen is covalently linked to the at least a portion of an HLA class Iα chain comprised within the immunomodulatory fusion protein.

8. The method of claim 7 , wherein the target peptide antigen comprises the sequence VMAPRTLFL (SEQ ID NO: 1).

9. The method of claim 1 , wherein the defined ratio comprises 80% of the first cell type.

10. An engineered heart muscle tissue comprising,

a mixture comprising a first cell type, at least one second cell type, and a biocompatible extracellular matrix, wherein

the first cell type is essential for the function of the engineered heart muscle tissue, wherein the first cell type is a cardiomyocyte, and wherein said first cell type is differentiated from a first population of modified ND50039 pluripotent stem cells comprising (i) a deletion of the β2-Microglobulin (B2M) gene endogenous to wild-type ND50039 cells, thereby preventing cell-surface expression of endogenous HLA-A, B, and C by the modified ND50039 cells, and (ii) introduction of an expression construct configured to drive cell-surface expression of an exogenous immunomodulatory fusion protein comprising at least a portion of B2M covalently linked to at least a portion of an HLA class Iα chain by the modified ND50039 cells,

the at least one second cell type forms a supporting component for the first cell type within the engineered heart muscle tissue, wherein the second cell type is a fibroblast and wherein said at least one second cell type is differentiated from a second population of modified ND50039 pluripotent stem cells comprising (i) a deletion of the β2-Microglobulin (B2M) gene endogenous to wild-type ND50039 cells, thereby preventing cell-surface expression of endogenous HLA-A, B, and C by the modified ND50039 cells, and (ii) introduction of an expression construct configured to drive cell-surface expression of an exogenous immunomodulatory fusion protein comprising at least a portion of B2M covalently linked to at least a portion of an HLA class Iα chain by the modified ND50039 cells into said at least one second cell type, and

the first cell type and the second cell type are mixed at a defined ratio,

thereby rendering the engineered heart muscle tissue to be non-immunogenic to a recipient of the engineered heart muscle tissue.

11. The engineered heart muscle tissue of claim 10 , wherein the defined ratio comprises 80% of the first cell type.

12. A method of treating a heart disease condition, comprising administering to a subject in need thereof an effective amount of the engineered heart muscle tissue of claim 10 .

13. The method of claim 12 , wherein the heart disease condition is selected from the group consisting of myocardial infarction and heart failure.

Priority Claims (1)
EP 18183294 · Jul 13, 2018 · regional
Continuity (1)
Related Publication 20210284965A1 · Sep 16, 2021
References Cited (55)
US 20080219956A1 · Russell et al. · 2008 [cited by applicant]
US 20180094245A1 · Kamp et al. · 2018 [cited by applicant]
US 20210363487A1 · Kamp · 2021 [cited by examiner]
WO 9209688A1 · 1992 [cited by applicant]
WO 2007054286A1 · 2007 [cited by applicant]
WO 2012145384A1 · 2012 [cited by applicant]
WO 2013047639A1 · 2013 [cited by applicant]
WO 2013158292A1 · 2013 [cited by applicant]
WO 2015025030A1 · 2015 [cited by applicant]
WO 2015040142A1 · 2015 [cited by applicant]
Hoare et al. Subtle changes in peptide conformation profoundly affect recognition of the non-classical MHC class I molecule HLA-E by the CD94-NKG2 natural killer cell receptors. J Mol Biol. Apr. 11, 2008;377(5):1297-303… [cited by examiner]
Kim K, et al. Epigenetic memory in induced pluripotent stem cells. Nature. Sep. 16, 2010;467(7313):285-90. doi: 10.1038/nature09342. PMID: 20644535; PMCID: PMC3150836. (Year: 2010). [cited by examiner]
International Search Report issued in PCT/EP2019/068944 on Sep. 10, 2019 (5 pages). [cited by applicant]
Written Opinion of the ISA issued in PCT/EP2019/068944 on Sep. 10, 2019 (6 pages). [cited by applicant]
Written Opinion of the IPEA issued in PCT/EP2019/068944 on Oct. 20, 2020 (21 pages). [cited by applicant]
Karabekian et al., “HLA Class | Depleted hESC as a Source of Hypoimmunogenic Cells for Tissue Engineering Applications”, Tissue Engineering: Part A, vol. 21, Nos. 19 and 20, 2015, DOI: 10.1089/ten.tea.2015.0105. [cited by applicant]
Lu et al., “Generating Hypoimmunogenic Human Embryonic Stem Cells by the Disruption of Beta 2-Microglobulin”, Stem Cell Reviews and Reports, 9, 806-813 (2013) (Abstract only). [cited by applicant]
Baghbaderani et al., cGMP-Manufactured Human Induced Pluripotent Stem Cells Are Available for Pre-clinical and Clinical Applications. Stem Cell Reports. Oct. 13, 2015;5(4):647-659. [cited by applicant]
Chou et al., Efficient human iPS cell derivation by a non-integrating plasmid from blood cells with unique epigenetic and gene expression signatures. Cell Res. Mar. 2011;21(3):518-529. [cited by applicant]
Didié et al., Parthenogenetic stem cells for tissue-engineered heart repair. J Clin Invest. Mar. 2013;123(3):1285-1298. [cited by applicant]
Ewart et al., Application of Microphysiological Systems to Enhance Safety Assessment in Drug Discovery. Annu Rev Pharmacol Toxicol. Jan. 6, 2018;58:65-82. [cited by applicant]
Gornalusse et al., HLA-E-expressing pluripotent stem cells escape allogeneic responses and lysis by NK cells. Nat Biotechnol. Aug. 2017;35(8):765-772. [cited by applicant]
Khan et al., AAV-mediated gene targeting methods for human cells. Nat Protoc. Apr. 2011;6(4):482-501. [cited by applicant]
Lancaster and Knoblich, Organogenesis in a dish: Modeling development and disease using organoid technologies. Science. Jul. 18, 2014;345(6194):1247125. [cited by applicant]
Lancaster et al., Cerebral organoids model human brain development and microcephaly. Nature. Sep. 19, 2013;501(7467):373-379. [cited by applicant]
Llonch et al., Organoid technology for retinal repair. Dev Biol. Jan. 15, 2018;433(2):132-143. [cited by applicant]
Lu et al., A defined xeno-free and feeder-free culture system for the derivation, expansion and direct differentiation of transgene-free patient-specific induced pluripotent stem cells. Biomaterials. Mar. 2014,35(9):281… [cited by applicant]
Morizane et al., Concise Review: Kidney Generation with Human Pluripotent Stem Cells. Stem Cells. Nov. 2017;35(11):2209-2217. [cited by applicant]
Ogle et al., Distilling complexity to advance cardiac tissue engineering. Sci Transl Med. Jun. 8, 2016;8(342):342ps13. [cited by applicant]
Okita et al., A more efficient method to generate integration-free human iPS cells. Nat Methods. May 2011;8(5):409-412. [cited by applicant]
Ott et al., Perfusion-decellularized matrix: using nature's platform to engineer a bioartificial heart. Nat Med. Feb. 2008;14(2):213-221. [cited by applicant]
Pagliuca et al.,Generation of Functional Human Pancreatic B Cells In Vitro. Cell. Oct. 9, 2014;159(2):428-439. [cited by applicant]
Rao et al, Engineering human pluripotent stem cells into functional skeletal muscle tissue. Nat Commun. Jan. 9, 2018;9(1):126 (12 pages). [cited by applicant]
Sawa et al., Safety and Efficacy of Autologous Skeletal Myoblast Sheets (TCD-51073) for the Treatment of Severe Chronic Heart Failure Due to Ischemic Heart Disease. Circ J. 2015;79(5):991-999. [cited by applicant]
Shimizu et al., Fabrication of Pulsatile Cardiac Tissue Grafts Using a Novel 3-Dimensional Cell Sheet Manipulation Technique and Temperature Responsive Cell Culture Surfaces. Circ Res. Feb. 22, 2002;90(3):e40-e48. [cited by applicant]
Song et al., Vascular Tissue Engineering: Progress, Challenges, and Clinical Promise. Cell Stem Cell. Mar. 1, 2018;22(3):340-354. [cited by applicant]
Soong et al., Cardiac differentiation of human embryonic stem cells and their assembly into engineered heart muscle. Curr Protoc Cell Biol. Jun. 2012;Chapter 23:Unit 23.8. [cited by applicant]
Sudo, Multiscale tissue engineering for liver reconstruction. Organogenesis. Apr.-Jun. 2014;10(2):216-224. [cited by applicant]
Takahashi and Yamanaka, Induction of Pluripotent Stem Cells from Mouse Embryonic and Adult Fibroblast Cultures by Defined Factors. Cell. Aug. 25, 2006;126(4):663-676. [cited by applicant]
Thomson et al., Embryonic Stem Cell Lines Derived from Human Blastocysts. Science. Nov. 6, 1998;282(5391):1145-1147. [cited by applicant]
Tiburcy et al., Collagen-based engineered heart muscle. Methods Mol Biol. 2014;1181:167-176. [cited by applicant]
Tiburcy et al., Defined Engineered Human Myocardium With Advanced Maturation for Applications in Heart Failure Modeling and Repair. Circulation. May 9, 2017;135(19):1832-1847. [cited by applicant]
Yang et al., Induced Neuronal Cells: How to Make and Define a Neuron. Cell Stem Cell. Dec. 2, 2011;9(6):517-525. [cited by applicant]
Ye et al., Patching the Heart: cardiac repair from within and outside. Circ Res. Sep. 13, 2013;113(7):922-932. [cited by applicant]
Zimmermann, Remuscularizing failing hearts with tissue engineered myocardium. Antioxid Redox Signal. Aug. 2009;11(8):2011-2023. [cited by applicant]
Zimmermann et al., Engineered heart tissue grafts improve systolic and diastolic function in infarcted rat hearts. Nat Med. Apr. 2006;12(4):452-458. [cited by applicant]
Cellosaurus, retrieved from https://www.cellosaurus.org/CVCL_RH36 on Oct. 11, 2023 (3 pages). [cited by applicant]
NIH News Release, Manufactured stem cells to advance clinical research, retrieved from https://www.nih.gov/news-events/manufactured-stem-cells-advance-clinical-research on Oct. 11, 2023 (4 pages). [cited by applicant]
Baghbaderani et al., “cGMP-Manufactured Human Induced Pluripotent Stem Cells Are Available for Pre-clinical and Clinical Applications”, Stem Cell Reports. Oct. 13, 2015;5(4):647-59. doi: 10.1016/j.stemcr.2015.08.015. Ep… [cited by applicant]
Kim et al., “Epigenetic memory in induced pluripotent stem cells”, Nature. Sep. 16, 2010;467(7313):285-90. doi: 10.1038/nature09342. [cited by applicant]
“Safety and Efficacy of Induced Pluripotent Stem Cell-derived Engineered Human Myocardium as Biological Ventricular Assist Tissue in Terminal Heart Failure (BioVAT-HF)”; ClinicalTrials.gov ID NCT04396899; Sponsor Univer… [cited by applicant]
Polo et a., “Cell type of origin influences the molecular and functional properties of mouse induced pluripotent stem cells”, Nat Biotechnol. Aug. 2010;28(8):848-55. doi: 10.1038/nbt.1667. Epub Jul. 19, 2010. [cited by applicant]
Poetsch et al., “Human Induced Pluripotent Stem Cells: From Cell Origin, Genomic Stability, and Epigenetic Memory to Translational Medicine”, Stem Cells. Jun. 22, 2022;40(6):546-555. doi: 10.1093/stmcls/sxac020. [cited by applicant]
Raab et al., “A Comparative View on Human Somatic Cell Sources for iPSC Generation”, Stem Cells Int. 2014:2014:768391. doi: 10.1155/2014/768391. Epub Nov. 6, 2014. [cited by applicant]
Office Action issued by the CIPO in related Canadian patent application No. 3105897 dated Jan. 29, 2025 (4 pages). [cited by applicant]